Showing 7471-7480 of 8889 results for "".
- Laseroptek Introduces Pallas UVB Laser in UShttps://practicaldermatology.com/news/laseroptek-introduces-pallas-uvb-laser-in-us/2460499/South Korea-based Laseroptek Co., Ltd. is launching the Pallas Solid-State 311nm UVB laser for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma in the United States. Pallas allows the choice of either 308 or 311 nanomet
- Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatologyhttps://practicaldermatology.com/news/verrica-enters-agreement-with-lytix-for-oncolytic-peptide-for-dermatology/2460498/Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinoma
- Membership Has Its Privileges: RealSelf Rolls Out RealSelf Insider Programhttps://practicaldermatology.com/news/membership-has-its-privileges-realself-rolls-out-realself-insider-program/2460496/RealSelf is introducing RealSelf INSIDER, a new membership program that offers cash rewards for cosmetic treatments as well as exclusive perks, including free virtual consultatio
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Rihanna Introduces Fenty Skinhttps://practicaldermatology.com/news/rihanna-introduces-fenty-skin/2460487/Rihanna, in partnership with Kendo Brands, is rolling out Fenty Skin. After years of feeling overwhelmed by all the skincare choices and a bad experience with a product that discolored her skin as a teen, Rihanna dreamed of creating a line that was easy and effective. Now, she'
- Stelara Approved for PsO in Kids Ages 6-11https://practicaldermatology.com/news/stelara-approved-for-pso-in-kids-ages-6-11/2460482/Stelara® (ustekinumab) is now approved for pediatric patients (6-11 years of age) with moderate to severe plaque psoriasis (PsO). Stelara, from The Janssen Pharmaceutical Companies of Johnson & Johnson, targets both interleukin (IL)-12 and IL-23
- Abbvie's Rinvoq Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitishttps://practicaldermatology.com/news/abbvies-rinvoq-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis/2460475/AbbVie's upadacitinib (Rinvoq) (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis. The co-primary endpoints were at least a 75 percent improvement in the Ecze
- Another New Patent for Alastin Skincarehttps://practicaldermatology.com/news/another-new-patent-for-alastin-skincare/2460473/Alastin Skincare, Inc. received a fourth U.S. Patent from the United States Patent and Trademark Office. The new patent, which incorporates TriHex Technology, is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum
- Mount Sinai Researcher Identifies Single Gene Biomarker to Differentiate Between Atopic Dermatitis and Psoriasishttps://practicaldermatology.com/news/mount-sinai-researcher-identifies-single-gene-biomarker-to-differentiate-between-atopic-dermatitis-and-psoriasis/2460472/Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The study, published in the Jou
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of